Juan J. Díaz-Mochón, Ph.D.
Chief Executive Officer,
DESTINA Genomics Ltd
Anitaben Tailor, Ph.D.
Biology Technical Marketing Manager, Merck KGaA, Darmstadt, Germany
Toxicity affects all facets of drug development. A guiding tenet in toxicity studies is to eliminate drug candidates that cause toxicity as early as possible. It is critical to identify biomarkers that are not only organ- or tissue-specific but also sensitive enough to identify damage before it becomes extensive.
microRNAs (miRNAs) fulfill the criteria for an ideal biomarker and show superior sensitivity compared to enzyme-based biomarkers.
Join this webinar to explore how to overcome sample prep and amplification challenges associated with miRNAs to get accurate ultrasensitive quantification without PCR. See how combining high-sensitivity immunoassays with cutting-edge miRNA detection technology empowers you to detect miRNA in biofluids with better reproducibility and ease of use.
You'll also discover why miR-122 has emerged as a novel biomarker for early detection of liver injury and explore the benefits of using it to evaluate drug safety profiles in the early stages of drug development such as minimizing financial loss due to late-stage drug failure.
In this webinar, you will learn:
- What makes miRNA a suitable biomarker for liver toxicity studies and its role in drug development;
- Why immunoassays are a critical tool in organ toxicity studies;
- How the latest technology enables early and accurate detection oflow-abundant liver toxicity biomarkers.
Webinar brought to you by
This webinar is sponsored by Merck KGaA, Darmstadt, Germany. MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.